CHF5993 vs CHF1535 vs placebo on lung hyperinflation and exercise endurance in COPD

Phase 4, randomised, double-blind trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium and beclometasone dipropionate + formoterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Change from baseline in 2-hour post-dose inspiratory capacity prior to constant work-rate cycle ergometry after 3 weeks of treatment. Started Feb 2021; status: completed.